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Abstract
Three myosin isozymes, V1 (αα MHC = Myosin Heavy Chain gene), V2 (αβ MHC) and V3 (ββ MHC) that are identified in
the cardiac ventricles of most mammals have been shown to shift to a V3 predominance pattern during cardiac growth and in
response to left ventricular pressure overload, and to V1 predominance following anti hypertensive treatment. This study
examined whether long-term hypertension impairs the ability of the adult heart to restructure myosin isozyme proportions. Using
pyrophosphate gel electrophoresis, we studied proportions of cardiac myosin isozymes (V1 and V3) in young (16 weeks) and
adult (36 weeks) spontaneously hypertensive rats (SHR), and following 12 weeks of nifedipine (N) treatment in age-matched
SHR rats (SHR-N). The values of V1 and V3 myosin isozymes were derived by adding half of the value of V2 to each isozyme
proportion. The V3 proportion in the young SHR control (SHR-C) group (49%) was 34% higher (p < 0.05) than in the young
Wistar Kyoto control (WKY-C) group (37%). However, the proportion was similarly high, though not statistically significant, in
both the adult SHRC (73%) and WKY-C (71%) groups. The proportion in the young SHR-N group (29%) was 41% lower (p <
0.05) than in the young SHR-C group (49%), and the proportion in the adult SHR-N group (47%) was 34% lower (p < 0.05) than
in the adult SHR-C group (73%). The ratio of left ventricular weight to body weight (LVW/BW), which determines left ventricular
hypertrophy (LVH), was higher in both young and adult SHR-C (26%, p < 0.05, and 42%, p < 0.05, respectively) than in WKY-C
groups. The mean LVW/BW was 27% (p < 0.05) greater in adult than in young SHR-C rats. The LVW/BW in both age groups of
treated SHR-N was similar to that in age matched WKY-C rats. Conclusion: Our study showed that a rise in the V3 level occurs
in young hypertensive rats, but no rise occurs in the V3 level in adult hypertensive rats. High blood pressure seems to contribute
to the high V3 level in young hypertensive rats, but in adult hypertensive rats, high blood pressure does not accentuate the V3
rise already acquired due to the aging process. Nifedipine treatment in both young and adult hypertensive rats prevented the
V3 rise due to hypertension and to the aging process. This effect of nifedipine seems to be through its antihypertensive action.
(Mol Cell Biochem 198: 109–112, 1999)
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Introduction
During the three stages of growth, development, and aging,
the rat myocardium undergoes structural, molecular genetic,
and protein synthetic changes which could cause its ability
to adapt to a variety of stimuli to be different in younger and
older rats [1]. Throughout the aging process, the myocardial
structural alterations include the development of left
ventricular hypertrophy (LVH) associated with cell loss, and
an increase in collagen deposition and fibrosis. At the
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biochemical and molecular genetic levels, of the three myosin
isozymes (V1, V2, V3), the V1, with higher ATPase and
higher V
max
, predominates throughout both the young and
adult life of the rats [2, 3]. With aging, however, the V1 level
decreases, while the V3 level, with low ATPase and low V
max
increases, resulting in V3 predominance in old rats [3, 4]. The
shift in myosin isozyme distribution toward a higher level of
V3 has been observed in response to mechanical pressure
overload due to aortic banding and renal hypertension,
regardless of age [1, 3]. In a recent study in old rats with
chronic genetic hypertension, we did not observe an increase
in V3 level [4]. In that study, the rise in V3 level in both old
normotensive and old hypertensive rats was only minimally
reduced with nifedipine; however, in another study we
observed the V3 rise to be completely reversed in normo-
tensive younger adult rats [5]. From these findings, it appears
that the strong adaptive capacity with respect to myosin
isozyme shift observed in young rats becomes diminished in
old rats. The hypothesis based on this observation in rats is
that the myocardium is well able to adapt to chronic hyper-
tension and to reverse consequent cardiac abnormalities in
young rats, but its ability diminishes with advancing age.
The aim of the present study was to characterize the myosin
isozyme adaptations in rats in response to (1) chronic
hypertension and (2) antihypertensive treatment as young rats
mature to adulthood. We used spontaneously hypertensive
rats (SHR) for this study because they are hypertensive from
an early age and throughout their life time, and are, therefore,
conducive to a study of evident myosin isozyme changes due
to on-going hypertension during growth and aging.
Materials and methods
Cardiac myosin isozyme proportions were studied in four
groups of SHR: (1) two age groups of controls (SHR-C), one
group aged 16 weeks (young) and one aged 36 weeks (adult),
and (2) two groups of SHR receiving nifedipine (SHR-N) for
12 weeks, one group from age 4–16 weeks (young), and one
from age 24–36 weeks (adult). The findings from the four SHR
groups were compared with the findings from two groups of
normotensive Wistar Kyoto control (WKY-C) rats of the same
age groups, 16 and 36 weeks from a previous study [5]. The
treatment regimen consisted of 26 ± 0.2 mg/g body weight/day
of nifedipine mixed with rat chow. Nifedipine dosage was the
same as that used to lower blood pressure in spontaneously
hypertensive rats in our laboratory [4, 5]. Systolic arterial
pressure (SAP) mmHg by tail-cuff was measured before the
initiation of the drug and at the end of the treatment period
in the treatment group, and in all other groups.
At the end of the 12-week treatment period, at ages 16 and
36 weeks, all rats were sacrificed under anesthesia (nembutal
50 mg/kg intraperitoneal). The heart was then removed and
the left ventricle (LV) including the interventricular septum
was dissected free from the atria, great vessels, and right
ventricle. The LV was dropped in a cryotube immersed in
liquid nitrogen and was used for myosin isozyme studies. The
body weight (BM) and LV weight (LVW) were measured, and
LV weight-to-body weight (LVW/BM ratio was calculated.
The protocol was approved by the University of New Mexico
Laboratory Animal Care and Use Committee.
Myosin isozyme study
Isolation of myosin and separation of myosin isozymes by
gel electrophoresis were accomplished as described in
previous studies [6, 7]. The gels were stained and destained,
and their densitometric scans were recorded on an E-C
apparatus attached to a Hewlett-Packard integrator (Model
3390A). The relative estimate of each isozyme was calculated
from the areas under the peak height. For the calculation of
V1 (αα Myosin Heavy Chain (MHC) gene) and V3 (ββ MHC)
content, the V2 (heterodimer, αβ MHC) isozyme was assumed
to be equally distributed between V1 and V3 isozymes. The
values of V1 and V3 myosin isozymes were derived by adding
half of the value of V2 to each isozyme proportion.
Statistical analysis
All results are expressed as the mean ± S.E.M. One-way
analysis of variance followed by the Newman-Keul’s pairwise
comparisons test was used to compare mean V3 levels among
the groups [8]. The same method was used to compare systolic
arterial pressure, LVW, BW, and the LVW/BW ratio among
the groups. Comparisons between time periods within the same
animal species were made using t-tests. Results are reported
as statistically significant if p < 0.05, or as NS if they were not
significant. Spearman correlation coefficients were calculated
to evaluate associations between V3 myosin isozyme, systolic
arterial pressure (SAP) both before and after treatment, LVW,
BW, and LV/BW in all subgroups of young and adult WKY-C,
SHR-C, WKY-N and SHR-N rats. The analyses were carried
out using the SAS statistical package for personal computers.
Results
The SAPmmHg in the SHR-C groups at both ages (16 and
36 weeks) was higher (170 ± 7 and 167 ± 5, respectively, p <
0.05 for both groups) than in the age-matched WKY-C (112
± 4, 130 ± 3, respectively). For SHR-C, no significant
difference in the SAP was observed between the two age
groups. The post-treatment SAP in both young and adult age
groups of the SHR-N rats was lower (152 ± 5 and 150 ± 1,
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respectively, p < 0.05 for both groups) than in the age-
matched SHR-C. The SAP level in both age groups of SHR-N
was lower relative to the age matched SHR-C groups (18 at
16 weeks and 17 at 36 weeks, p < 0.05 for both values).
However, the level in the SHR-N groups was significantly
higher (p < 0.05) than in the age-matched WKY-C.
Physical characteristics and V3 proportion for all groups
are given in Table 1, with values of these parameters in
age-matched WKY rats from our previous published study
[5]. The question(s) posed in the present work concerns
whether or not the change in the V3 level and LVH with
hypertension and anti hypertensive treatment is different in
the young vs. the adult SHRs. In the young SHR-C, mean
LVW was 26% higher (p < 0.05) than in the young WKY-C,
and the mean BW was similar to that in the young WKY-C.
In the adult SHR-C, mean LVW was 31% higher and mean
BW was 8% lower than in the adult WKY-C. Mean LVW/
BW ratio was higher in both the young and adult SHR-C (26
and 42% higher, respectively, p < 0.05 for both values) than
in the age-matched WKY-C. The mean LVW/BW ratio in
adult SHR-C was 27% (p < 0.05) greater than in the young
SHR-C. No statistically significant difference in the mean
LVW/BW ratio was found between the adult and young
SHR-N. Mean LVW/BW ratio was 18% (p < 0.05) higher in
young SHR-N than in the young WKY-C; but not statistically
different between the adult SHR-N and the adult WKY-C.
The V3 proportion was substantially increased in the young
SHR-C vs. the young WKY-C (34% higher, p < 0.05), but
was not significantly increased in the adult SHR-C vs. the
adult WKY-C (3% higher; NS). The proportion was lower
in both young and adult SHR-N vs. age-matched SHR-C (41
and 34% lower, respectively, p < 0.05 for both values).
Furthermore, in both young and adult SHR-N, the V3
proportion was lower than that in the age-matched WKY-C
(21%, NS, and 35%, p < 0.05, respectively).
Because of the observed difference in the V3 level between
the young SHR-C vs. the adult SHR-C, correlations were
calculated to determine whether the V3 level in the SHR-C
and SHR-N groups was associated with SAP and LVH, with
and without treatment. The V3 level in young SHR-C was
significantly related only to pretreatment SAP (r = 0.97, p <
0.001), and not to LVW (r = –0.21, p = 0.74), BW (r = 0.48,
p = 0.33), or to LVW/BW ratio (r = 0.10, p = 0.87). The V3
level in the adult SHR-C was related neither to pretreatment
SAP nor to any parameter of LVH: pretreatment SAP (r =
–0.40, p = 0. 33), LVW (R = –0. 04, p = 0. 93), BW (r = 0.42,
p = 0.30), or to LVW/BW (r = –0.50, p = 0.20). The V3 level
in the young SHR-N was significantly related to the post-
treatment SAP (r = 0.84, p = 0.04), but not to pretreatment SAP
(r = –0.34, p = 0.51), LVW (R = 0.14, p = 0.78), BW (r = 0.64,
p = 0.17), or to LVW/BW (r = –0.26, p = 0.62). Similarly, the
V3 level in the adult SHR-N was significantly related to the
post-treatment SAP (r = 0.80, p = 0.02), but not to pretreatment
SAP (r = –0.06, p = 0.88), LVW (r = 0. 14, p = 0.74), BW (r =
0.46, p = 0.26), or to LVW/BW (r = –0.24, p = 0.57).
Discussion
Two major cardiac adaptations to pressure overload are LVH
and a myosin isozyme shift toward V3 predominance [1, 3,
7]. The rat heart at all ages, including very young and very
old, responds in this manner to acute pressure overload [1,
3, 7]. However, our data show that with chronic pressure
overload as in systemic hypertension, both these responses
do not occur at all ages. Our study showed that in chronically
hypertensive rats, the young rats developed both LVH and a
rise in V3, but the adult rats developed LVH with no con-
comitant rise in V3.
The specific triggers leading to up-regulation of the
β-MHC gene and an increase in V3 level in response to left
ventricular pressure overload are not known. However, the
stimulus of high LV wall stress resulting from an acute
increase in LV pressure has been linked with the α- to β-MHC
switch and greater synthesis of V3 isozyme, and with LVH
development [9]. In support of this view, studies [9, 10] have
demonstrated an accumulation of β-MHC mRNAs after
aortic banding first in the endocardium and in the areas
surrounding coronary arteries and then in the rest of the
myocardium [9], an increase in myocardial protein synthesis
following acute increases in aortic pressure in isolated heart
preparations, and an increase in the mRNA synthesis in
isolated cardiac nuclei subjected to hydrostatic pressure [10].
Based on these findings, we believe that high LV wall stress
is a major stimulus for the observed rise in V3 in young SHRs
with recent onset hypertension. It is likely that in this age
group, the moderate LVH is not sufficient to normalize the
wall stress. With long-term hypertension as in the adult SHR
Table 1. Physical characteristics and V3 myosin isozyme level in untreated
control (SHR-C) and nifedipine treated (SHR-N) spontaneously hyper-
tensive rats, and age-matched Wistar Kyoto control *(WKY) rats
Age/wks WKY-C SHR-C SHR-N
LVW 16 0.70 ± 0.02a,d 0.88 ± 0.06d 0.86 ± 0.02d
36 1.03 ± 0.05 1.35 ± 0.03b 0.98 ± 0.03
BW 16 362 ± 8d 362 ± 8d 379 ± 8d
36 477 ± 4a 437 ± 7 445 ± 5
LVW/BW 16 1.92 ± 0.05a,d 2.42 ± 0.18d 2.27 ± 0.05
36 2.17 ± 0.10 3.08 ± 0.06b 2.20 ± 0.05
V3 16 36.60 ± 2.79d 49.17 ± 5.33b,d 29.00 ± 2.94d
36 70.60 ± 1.12 72.63 ± 1.71 46.88 ± 2.72c
Results from a previous study [5]. Data, mean ± S.E.M.; ap < 0.05 vs. SHR-C
and SHR-N within the same age group; bp < 0.05 vs. WKY-C and SHR-N
within the same age group; cp < 0.05 vs. SHR-C and WKY-C within the
same age group; dp < 0.05 16 vs. 36 weeks within the specific animal group;
LVW – left ventricular weight; BW – body weight.
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group in the present study, further increase in left ventricular
wall thickness by hypertrophy could restore the wall stress to
within normal limits, and thus reduce the stimulus responsible
for a V3 rise. Consistent with this view, our data dem-
onstrated an association between V3 level and SAP in young
SHRs (r = 0.97, p < 0.001), but not in adult SHRs (r = 0.40,
p = 0.33).
The absence of a rise in V3 proportion in adult SHRs raises
the question of whether adult chronically hypertensive rats
are unable to alter myosin isozymes. This question is based
on several earlier studies [11, 12, 13] according to which
both aging and hypertension impair the ability of the heart
to alter gene expression and to synthesize proteins. In the
present study, the adult SHRs were able to achieve a V3
level as high as their age-matched normotensive counter-
parts. In addition, the level was substantially lower in adult
SHRs treated with nifedipine. These findings and the 43%
increase in LVH in adult SHRs vs. adult WKYs argue
against an age- and hypertension-associated impairment in
molecular and biochemical adaptations in the adult rat heart.
Nifedipine treatment resulted in lower V3 proportion, and
SAP and LVH reduction in both young and adult SHRs. The
V3 proportion in both young and adult SHRs was related
to post-treatment SAP, but not to LVH. Based on these data,
the lower V3 level in nifedipine-treated SHRs could be
attributed to the drug’s anti hypertensive action. Because the
decrease in the V3 level with nifedipine occurred despite
moderate residual hypertension, the V3 to V1 shift could
also be due to a direct action of the drug on the heart which
was in addition to its anti hypertensive effect. This view is
supported by findings in our previous study [5], in which
nifedipine prevented the age-related rise in V3 levels in
WKYS. Nifedipine has been shown to decrease a number
of functional calcium channels secondary to myocardial
hypertrophy [14], thereby decreasing calcium entry into the
myocytes and ameliorating the calcium overload, and thus
inhibiting the factor(s) that contribute to greater β-MHC
synthesis. Another possible mechanism is that nifedipine
enhances synthesis of the α-myosin gene by a direct effect
on gene transcription [15].
The present study suggests that the ability to restructure
myosin isozyme composition and to modify LVH in response
to chronic hypertension and anti hypertensive treatment is not
impaired with hypertension and the aging process. However,
the pattern of these adaptive responses in chronic hyper-
tension is not similar in the young and the adult rats. High
blood pressure contributes to high V3 level in young SHRs
but not in adult SHRs. The high V3 level in adult SHRs is
principally due to the aging process, without any additional
contribution from the high blood pressure or LVH. Treatment
with nifedipine prevents a rise in V3 in both young and adult
SHRS. This effect of nifedipine seems to be through its anti
hypertensive action.
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